This study examined apolipoprotein (apo) B metabolism in normolipemic subjects homozygous for the apo E2 (n = 4), apo E3 (n = 5), or apo E4 (a = 5) phenotype. Radioiodinated very low density lipoprotein (VLDL1) (ultracentrifuge flotation rate 1Sf 60-400) and VLDL2 (Sf 20-60) were injected into volunteers and the conversion of apo B was followed through intermediate density lipoprotein (IDL) to low density lipoprotein (LDL). Subjects homozygous for E3 converted -50% of VLDL2 to LDL, the remainder being lost by direct catabolism. Those with the E2 phenotype produced less VLDL1 but converted more of it to VLDL2 (compared to E3 subjects). They displayed a characteristic dyslipidemia with the presence of slowly catabolized VLDL, and VLDL2 remnants. LDL levels were low owing to increased direct catabolism of VLDL2 and IDL and a reduced efficiency of delipidation; only 25% of VLDL2 apo B was directed to LDL production. In contrast, E4 subjects converted more VLDL2 apo B to LDL than E3 subjects. About 70% of VLDL2 apo B was found in LDL; direct catabolism of VLDL and IDL was reduced as was the fractional catabolic rate of LDL (0.2 vs. 0.26 in E3 subjects). These changes in the VLDL -* IDL --LDL metabolic cascade can in part be explained by alterations in hepatic LDL receptors with E2 subjects having higher and E4 subjects lower activities than those in E3 homozygotes. (J. Clin. Invest. 1991. 88:1490-1501
Introduction
In humans the gene locus for apolipoprotein E (apo E) is polymorphic with three alleles (E2, E3, and E4) being present in all populations studied so far (1) (2) (3) . The commonest variant is E3 for which -70% ofCaucasians are homozygous. It codes for a protein of 299 amino acid residues, which although minor in terms of plasma concentration, has an important role in regulating lipoprotein metabolism by virtue of its ability to act as a ligand for specialized lipoprotein receptors. Individuals who possess the E2 allele synthesize an apo E in which the arginine residue at position 158 is replaced with cysteine as the result of a C --T point mutation. Those with E4 in contrast generate a product with an arginine at residue 1 12 compared with cysteine in apo E3. These mutations in the protein sequence cause charge changes which are readily detected by isoelectric focusing of very low density lipoproteins (VLDL) apoproteins (4) or by isoelectric focusing of plasma followed by detection with immunoblotting (5, 6) . Structure-function studies of apo E have revealed that a domain covering amino acid 140-160 is of critical importance in receptor interaction. The E2 mutation occurs in this region and in vitro studies have demonstrated that the resulting protein has impaired receptor-binding properties (4, 7) .
Epidemiological surveys have demonstrated that the apo E polymorphism has a significant impact on plasma cholesterol and apolipoprotein B (apo B) levels (3) . Compared to apo E3 homozygotes, those who are homozygous for the E2 allele exhibit plasma cholesterol levels that are 10-15% lower while the opposite holds for those who are E4 homozygotes. Examination of the lipoprotein profile in the various apo E phenotypes has revealed that the gradation in plasma cholesterol from E2 to E3 to E4 homozygotes is due to an increase in the level of low density lipoprotein (LDL). However, E2 homozygotes have higher VLDL cholesterol levels and display a dyslipidemia that is qualitatively similar to that seen in type III hyperlipidemia. The latter is usually associated with E2 homozygosity and inheritance of another as yet unidentified mutation that causes an elevation of plasma lipid levels (8) . A number of studies have examined the metabolic changes underlying the altered lipoprotein profiles associated with the apo E polymorphism. Chylomicron clearance is reduced in subjects possessing the E2 allele, whereas E4 heterozygotes and homozygotes show accelerated clearance (9, 10) . Metabolic studies of LDL apo B have shown that type III and, to a lesser extent, E2 homozygous subjects degrade LDL faster than normal (11, 12) . Previous studies from this laboratory have examined VLDL, intermediate density lipoprotein (IDL), and LDL apo B metabolism in a number of genetically determined dyslipidemias. In particular, we found in patients with homozygous familial hypercholesterolemia that the LDL receptor was important not only in LDL catabolism but also in the processing ofapo B-containing lipoproteins throughout much ofthe delipidation cascade from VLDL to LDL (13) . Since apo E is important for lipoprotein receptor interaction, we surmised that structural and functional variation in this protein would modulate the metabolism of the lipoproteins within the entire ultracentrifuge flotation rate (Sf)1 0-400 spectrum. To investigate this, we conducted VLDL turnover studies in groups of individuals homozygous for the three E variants. The results demonstrate the profound impact that this polymorphism has on apo B metabolism.
Methods
Subjects. The study participants were selected from individuals who attended a coronary screening program in health centers in Glasgow. The Institute of Biochemistry received samples for cholesterol assay as part ofthe screen and those in which the level lay in the range of5.0-6.2 mmol/liter (195-240 mg/dl) were subjected to apo E phenotyping using the isoelectric focusing/immunoblotting technique described below. Subjects who were found to be homozygous for the presence of apo E2 (n = 4), apo E3 (n = 5), or apo E4 (n = 5) were recruited for the study. For ease of presentation throughout this report subjects are referred to as the E2, E3, or E4 group to denote phenotypically determined homozygosity for the E2, E3, or E4 alleles (14) . have been described in detail in previous publications (18) . Briefly, 250 ml of plasma was removed by plasmapheresis from subjects who had been fasted overnight and total VLDL of d < 1.006 g/ml (S$ 20-400) ( 13) of the cumulative gradient ultracentrifugation (20) . From these apo B was isolated by tetramethylurea (TMU) precipitation (21) and its specific activity was determined by radioactivity counting and protein determination (22) . The apo B pool circulating with each of these lipoprotein fractions was determined by replicate analyses ofplasma samples collected intermittently throughout the turnover study. Correction was made for possible B protein loss during TMU precipitation by comparing the apo B recovered at the end of the procedure with the values calculated as the difference between total and TMU-soluble (apo E and C) protein contents (21) . The composition of each fraction was determined by assay of total and esterified cholesterol, triglyceride, phospholipid, and protein (23). Protein determinations were performed with the addition of sodium dodecyl sulfate to the Biuret reagent (22) .
Subjects received potassium iodate in tablet form (180 mg/d) for 3 d before and 1 mo after injection to block thyroidal sequestration of radioactive iodine released by catabolism.
Kinetic analysis. The radioactivity associated with the apo B protein present in each lipoprotein fraction was calculated from the apo B specific activities and the individual pool sizes. These were expressed as a percentage of the total apo B radioactivity (i.e., VLDL1 plus VLDL2, IDL, and LDL) present in the plasma 10 min after injection and the resulting values were used to construct decay curves which were analyzed by the SAAM 30 (24) multicompartmental modeling program. The metabolic model employed ( Fig. 1) of VLDL1 and VLDL2 tracers is shown in Fig. 2 . In order to examine intergroup differences more closely, the observed data at each time point were averaged within group and are presented as a mean and standard error for the E2, E3, and E4 subjects. Individual decay curves and apo B masses were used in multicompartmental modeling to generate the kinetic parameters given in Tables IV and V. VLDL, apo B radioactivity was cleared rapidly from the plasma of E3 and E4 homozygotes (Fig. 2 a) . The decay curve was monoexponential and only -1% remained at the last time point on the first day, 14 h after injection. Clearance of this lipoprotein was slower in E2 subjects with -10% remaining at 14 h. The decay curve in the last group was biexponential containing a slow component which accounted for up to 10% of the apo B present in the VLDLJ tracer. This feature necessitated the addition to the model of a second compartment (compartment 12) in VLDL, (Fig. 1) . VLDL, apo B appeared in VLDL2 with a peak radioactivity -5 h after injection in all subjects (Fig. 2 b) . Transfer of VLDLI to VLDL2 was greater and catabolism of apo B from VLDL2 was slower in E2 compared with E3 and E4 subjects. The latter was true whether label in this fraction was introduced directly as a VLDL2 tracer or derived from VLDLI.
The metabolism of IDL derived from both tracers (Fig. 2 c) was similar in all three groups. Radioactivity peaked at 8-10 h and decayed in a multiexponential fashion, slightly faster in E3 than in E2 or E4 subjects. Substantial differences however were observed in the metabolic behavior of LDL apo B. Peak radioactivity values of 20% for the VLDL, apo B tracer and 35%
for the VLDL2 apo B tracer were observed in LDL for E3 and E4
homozygotes. In contrast, < 5% and 12% of apo B radioactivity derived from the VLDL, and VLDL2 tracers, respectively, was seen in the LDL fraction of E2 subjects. The decay curve for LDL apo B in E3 homozygotes appeared to decline more sharply than that for the E4 group, particularly over the first 5 d of the turnover.
There was little difference in VLDL, apo B pool size in the three groups (Table IV a) in concordance with their similar plasma triglyceride levels (Table I) . Apo B in this flotation interval was synthesized at about 800 mg/d and cleared at a rate .001
Time (hours) (27) . LDL apo B was divided into two metabolically distinct pools to account for the observation that apo B derived from VLDL2 appeared and was cleared more rapidly than material derived from VLDL, (13, 18) .
Apo B metabolism in E2 homozygotes. The metabolism of VLDL, apo B differed in E2 compared with E3 subjects in three aspects. First, the decay curve was biexponential probably as a result of the presence of chylomicron remnants. It has been shown that subjects homozygous or heterozygous for the apo E2 phenotype clear chylomicrons slowly and therefore remnants are likely to be present even after a 12-h fast (9, 10).
Remnant accumulation is a hallmark of type III hyperlipidemia, and we noted that the VLDL, apo B curves observed in the present E2 group were qualitatively similar to those found previously in type III subjects (18) . The slowly metabolized species in the VLDL, fraction in the present study was estimated at 10% ofthe apo B mass but direct quantitation ofB48 vs. B100 in the tracer (a measure ofchylomicron remnant content) was not performed. Secondly, the rate of VLDL, apo B synthesis was significantly reduced in comparison to the E3 subjects. The reason for this is not clear although it is possible that impaired delivery of chylomicron lipid to the liver in E2 homozygotes causes that organ subsequently to secrete less triglyceride-rich VLDL. Thirdly, there was less direct catabolism of VLDLI apo B. This pathway accounted for 25% of VLDLJ clearance compared with 65% in E3 subjects (Table IV a). As mentioned above this unknown mechanism of apo B catabolism operates in most normal and hyperlipidemic subjects. Its decreased activity in E2 homozygotes indicates that functional apo E may be required for it to proceed efficiently and raises the possibility that a receptor may be involved. It is unlikely that the classical LDL receptor has a substantial role in this regard since the pathway works as normal in FH (13) . There is evidence that the recently discovered LDL receptor-related protein has apo E-binding properties (31) and is a candidate agent for mediating chylomicron remnant removal. If very large triglyceride-rich VLDL were catabolized in a similar fashion to chylomicrons, then this would explain the decreased removal in E2 homozygotes. Indeed, in vitro apo E2 shows impairment in binding to the LDL receptor-related protein (32) . Apo B synthesis into VLDL2 whether de novo or from VLDL1 occurred at the same rate in E2 and E3 subjects (Table  IV b ). More apo B passing through the delipidation chain in E2 homozygotes was diverted to remnants and the expansion of this presumably cholesteryl ester-rich population of particles in VLDL2 to 13% oftotal apo B mass (compared to < 2% in E3 subjects, Table V c) explains the abnormal composition ofthis lipoprotein fraction in the E2 group (Table II) . Surprisingly the catabolic rate of VLDL2 remnants [L(9, 6) and L(0, 6), Table  V] was not consistently reduced in our E2 subjects. IDL formation and clearance occurred at approximately the same rate in E2 and E3 subjects. However, the metabolic fate of apo B differed greatly between them with a 66% reduction in the rate of LDL formation in the former. This difference was the principal cause of reduced LDL levels in E2 homozygotes. The data in Tables IV and V indicate that in E2 subjects the impaired IDL to LDL conversion is balanced by increased catabolism of the intermediate fraction: an observation that suggests that functional apo E is not required for effective IDL clearance. Direct removal of IDL probably occurs via LDL receptors since it is inhibited by 1,2-cyclohexanedione modification ofthe lipoprotein (27) and is depressed in homozygous FH (13) . In fact, there was no inhibition of VLDL2, IDL or LDL clearance in our E2 subjects suggesting either that it is apo B that acts as the ligand for receptors in these lipoproteins fractions (as is found in vitro [33, 34] ) or that an increase in receptor activity more than compensates for the reduced affinity ofapo E2 for the receptor. The reason why direct IDL catabolism is favored over conversion to LDL in E2 homozygotes is unknown. The phenomenon was recorded previously in our study of the effects of bezafibrate on apo B metabolism in type III hyperlipidemic subjects (35) . These were apo E2 homozygotes with elevated lipid levels that were corrected by bezafibrate therapy. The mean on-therapy concentrations of plasma cholesterol, triglyceride, VLDL, LDL, and HDL cholesterol were 5.87, 2.12, 1.63, 2.79, and 1.46 mmol/liter, respectively; values close to those seen in our normolipemic E2 group (Table I) . Apo B kinetics in the type III 5  56  52  3  50  301  6  32  48  3  148  761   7  34  62  6  98  500  8  43  99  6  70  280   9  18  1 1  2  39  203  Median  34  52  3  70  301   10  38  172  3  77  273  1 1  53  91  2  24  180  12  19  58  10  32  480  13  10  32  2  12  173  14  18  35  2  25  332  Med-ian  18R  58   2  25  273 Table V Table IV) , whereas on treatment this fell to 26%, i.e., close to the value seen in normolipemic E2 subjects. Thus bezafibrate had two effects; it reduced VLDL synthesis correcting the hyperlipidaemia (but not the dysbetalipoproteinemia) and altered the nature of the IDL to LDL metabolic link from that seen in E3 to that seen in E2 subjects. There was no increase in the fractional clearance rate of LDL apo B in E2 homozygotes in the present study (Table IV  d ). This contrasts with an earlier preliminary report by Gregg et al. (12) in which a small increase in LDL FCR was observed in two normolipemic E2 homozygotes. However, further work by the same authors in an apo E-deficient patient demonstrated a normal catabolic rate for autologous LDL apo B (36, 37) . The low LDL apo B level observed in that condition was due to reduced synthesis at 20% of normal and in general LDL kinetics in apo E deficiency were similar to those reported here for E2 subjects (Table IV d) .
Apo B metabolism in E4 homozygotes. Apo B synthesis in VLDL1 was lower in E4 than E3 subjects (Table IV a) but the difference was not significant. The circulating mass of apo B and clearance rate of the fraction were similar in the two groups. Likewise, VLDL2 apo B synthesis, pool size, and overall catabolic rate were similar in E3 and E4 subjects as was the turnover of IDL (Table IV) . However, calculation of the amount of apo B undergoing direct catabolism from VLDL2 and IDL compared to that channeled down the delipidation cascade revealed that E4 homozygotes exhibited a relative decrease in direct removal and, per milligram of apo B entering VLDL2, directed more towards LDL production (Table IV) . Thus, despite the fact the E4 subjects synthesized apo B in VLDL (VLDL1 plus VLDL2) at only two-thirds ofthe rate seen in E3 homozygotes (Table IV a and b) they had apo B levels that were at least as high as those seen in the latter group (Table II) . LDL levels in E4 subjects were further increased by the low FCR seen for apo B in this flotation interval (Tables IV dand V  e) . This was due to a decrease in the rate of apo B degradation from the larger of the two LDL compartments (compartment 10, (38) and chylomicron kinetics (9, 10) to generate an overall picture of the influence of the polymorphism which refines and in places corrects the model previously suggested by Davignon et al. (3) . Cholesterol absorption from the gut is reportedly higher in E4 vs. E3 vs. E2 subjects. This together with differential clearance rate ofchylomicron remnants (E4> E3> E2; references 9 and 10) will affect the delivery of intestinal (including dietary) cholesterol to the liver. The result is a predicted decrease in the hepatic sterol pool in E2 vs. E3 and E4 subjects which gives rise to the observed graded difference (E2> E3> E4) in the rates of cholesterol and bile acid production (38, 39) . According to current concepts changes in the liver cholesterol pool will alter hepatic LDL receptor activity. The latter is predicted to be higher in E2 compared to E3 subjects and they in turn will be higher than E4 subjects. Since we have found previously that LDL receptors play a role in VLDL2, IDL, and LDL metabolism (13, 27) , this mechanism explains why E2 homoz) gotes exhibit more and E4 homozygotes less direct catabolism of VLDL2 and IDL than E3 subjects. In this scenario LDL removal should be increased in E2 homozygotes but this was not observed in our group (Table IV d) or in an apo E-deficient patient (37) possibly because the small amount of LDL that is present is abnormal, having a conformation of apo B that fails to recognize receptors efficiently. Evidence to support this hypothesis comes from studies of the kinetic behavior of LDL from apo E-deficient or E2 homozygous subjects in normals; it is cleared more slowly than autologous LDL (12, 37) . In contrast, normal LDL given to an apo E-deficient patient is cleared rapidly as would be the case if LDL receptors were up-regulated (37) . The redirection ofthe metabolic fate of IDL from conversion to LDL to direct catabolism in E2 homozygotes may be further influenced by a requirement for functional apo E for lipolysis to proceed efficiently. In vitro studies suggest that VLDL from E2 subjects is not a good substrate for lipase and lipolysis of this lipoprotein does not lead to the formation of LDL (40) . Addition of apo E3 enhances the reaction and LDL is formed. Retarded delipidation would provide a mechanism for the formation ofVLDL2 remnants and the very low conversion of IDL to LDL in our E2 subjects. This integrated model, which is now modified and considerably strengthened by the availability of detailed apo B kinetic data, can be used to help explain why individuals with varying apo E phenotypes respond differently to diet and drug therapies (41, 42) .
